☆ 4.6 Letter

Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia

BRITISH JOURNAL OF HAEMATOLOGY (2017)

Get Full Text
Add to Collection

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume 177, Issue 3, Pages 486-491

Publisher

WILEY
DOI: 10.1111/bjh.14066

Keywords

idelalisib; TP53 deletion; TP53; B-cell prolymphocytic leukaemia; prolymphocytic leukaemia

Categories

Hematology

Funding

  1. Julian Starmer-Smith Lymphoma Fund
  2. NIHR Biomedical Research Centre (Oxford)

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.